Concepedia

Essential thrombocytemia following immune thrombocytopenia with JAK2V617F mutation

Giovanni Caocci, Sandra Atzeni, Monica Usai, Giorgio La Nasa

Leukemia Research Reports · 2017 · 10 citations · 8 references

DOIFull text

Open access

Concepts

Abstract

positive clone (3%) raised to 27% in the following years. The association of ET and ITP could suggest similar pathogenetic mechanisms that should be further investigated.

References

8

Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders

Valerio De Stefano, Alessia Fiorini, Elena Rossi et al. · Journal of Thrombosis and Haemostasis · 2007 · 203 citations · Full text

, , +13

Autoimmunity and the risk of myeloproliferative neoplasms

Sigurður Y. Kristinsson, Ola Landgren, Jessica Samuelsson et al. · Haematologica · 2010 · 190 citations · Full text

, , +11

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms

William Tapper, Amy V. Jones, Róbert Královics et al. · Nature Communications · 2015 · 163 citations · Full text

, , +15

The JAK2 V617F somatic mutation, mortality and cancer risk in the general population

Camilla Munch Nielsen, Henrik Birgens, Børge G. Nordestgaard et al. · Haematologica · 2010 · 131 citations · Full text

, , +16

JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate

Camilla Friis Bryde Nielsen, Stig E. Bojesen, Børge G. Nordestgaard et al. · Haematologica · 2014 · 101 citations · Full text

, , +13